MedPath

Pacing the Atrium to Confirm or Exclude Pacemaker Indication in TAVI

Recruiting
Conditions
Aortic Valve Stenosis
Registration Number
NCT05278585
Lead Sponsor
AZ Sint-Jan AV
Brief Summary

The current observational registry aims to evaluate in patients undergoing TAVI implantation:

1. the positive and negative predictive value for PPM post TAVI of Wenckebach phenomenona (WB) during RAP during the TAVI procedure,

2. baseline and procedural characteristics of TAVI-implantation associated with new conduction abnormalities and need for PPM implantation,

3. peri-procedural safety, in-hospital and 1-month outcomes after TAVI implantation.

Detailed Description

The persistent growth in transcatheter aortic valve implantation (TAVI) calls for optimized early discharge programs to handle the increasing patient load. While access site bleeding and stroke rate have decreased with improved technologies and operators' experience, acquired conduction abnormalities necessitating prolonged rhythm-monitoring and permanent pacemaker (PPM) implantation have remained largely unchanged, and even up to 39.9% for some TAVI platforms. Prompt identification of patients necessitating PPM implantation leads to optimal patient care and use of resources. Conversely, prompt identification of patients with low -to no- risk for PPM post TAVI shortens their hospitalization and facilitates early and safe discharge.

Several baseline characteristics such as age, preexistent right bundle branch block (RBBB) and the use of self-expanding valves are associated with post-TAVI PPM implantation, but more practical and clinically more relevant parameters are needed with high negative and positive predictive values that could support clinical decision-making.

En passant rapid atrial pacing (RAP) immediately following TAVI has recently been reported to be a valuable tool in PPM risk stratification. The absence of Wenckebach phenomena post implantation at RAP up to 120/' has a negative predictive value for PPM of 98.7%.2 First use of RAP in routine practice at AZ Sint Jan Brugge can confirm these first results (unpublished data). This technique improves our clinical assessment and identification of low-risk patients for PPM suitable for safe early discharge, as well as high-risk patients requiring further rhythm monitoring and eventual PPM implantation.

The current observational registry aims to evaluate in patients undergoing TAVI implantation:

1. the positive and negative predictive value for PPM post TAVI of Wenckebach phenomenona (WB) during RAP during the TAVI procedure,

2. baseline and procedural characteristics of TAVI-implantation associated with new conduction abnormalities and need for PPM implantation,

3. peri-procedural safety, in-hospital and 1-month outcomes after TAVI implantation.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
500
Inclusion Criteria
  • All patients in sinus rhythm with TAVI
Exclusion Criteria
  • Patients in atrial fibrillation at the time of the implantation
  • Patients with pre-existent pacemaker

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Positive and negative predictive value of RAP for PPM implantation post TAVI1 month after TAVI
Permanent pacemaker implantation1 month after TAVI
New conduction abnormalitieswithin 1 week after TAVI
Secondary Outcome Measures
NameTimeMethod
Stroke1 month after TAVI
Duration of hospitalization1 month after TAVI
Echocardiographic changes1 month after TAVI
Major vascular bleeding1 month after TAVI
New pericardial effusion1 month after TAVI
All-cause mortality1 month after TAVI

Trial Locations

Locations (12)

Algemeen Stedelijk Ziekenhuis Aalst

🇧🇪

Aalst, Belgium

OLV Aalst

🇧🇪

Aalst, Belgium

ZNA Middelheim

🇧🇪

Antwerp, Belgium

AZ Sint Jan

🇧🇪

Brugge, Belgium

CHU Charleroi-Chimay

🇧🇪

Charleroi, Belgium

Grand Hôpital de Charleroi

🇧🇪

Charleroi, Belgium

Ziekenhuis Oost-Limburg

🇧🇪

Genk, Belgium

UZ Brussel

🇧🇪

Jette, Belgium

UZ Leuven

🇧🇪

Leuven, Belgium

Citadelle Hospital

🇧🇪

Liège, Belgium

Scroll for more (2 remaining)
Algemeen Stedelijk Ziekenhuis Aalst
🇧🇪Aalst, Belgium
An Roets
Contact
Liesbeth Rosseel, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.